E-viri
PDF
Recenzirano
Odprti dostop
-
Mikhael, Joseph R., MD; Dingli, David, MD, PhD; Roy, Vivek, MD; Reeder, Craig B., MD; Buadi, Francis K., MD; Hayman, Suzanne R., MD; Dispenzieri, Angela, MD; Fonseca, Rafael, MD; Sher, Taimur, MD; Kyle, Robert A., MD; Lin, Yi, MD, PhD; Russell, Stephen J., MD, PhD; Kumar, Shaji, MD; Bergsagel, P. Leif, MD; Zeldenrust, Steven R., MD, PhD; Leung, Nelson, MD; Drake, Matthew T., MD, PhD; Kapoor, Prashant, MD; Ansell, Stephen M., MD, PhD; Witzig, Thomas E., MD; Lust, John A., MD, PhD; Dalton, Robert J., MD; Gertz, Morie A., MD; Stewart, Keith, MBChB; Rajkumar, S. Vincent, MD; Chanan-Khan, Asher, MD; Lacy, Martha Q., MD
Mayo Clinic proceedings, 04/2013, Letnik: 88, Številka: 4Journal Article
Abstract Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. There has been a veritable revolution in this disease during the past decade, with dramatic improvements in our understanding of its pathogenesis, the development of several novel agents, and a concomitant doubling in overall survival. Because multiple myeloma is a complex and wide-ranging disorder, its management must be guided by disease- and patient-related factors; emerging as one of the most influential factors is risk stratification, primarily based on cytogenetic features. A risk-adapted approach provides optimal therapy to patients, ensuring intense therapy for aggressive disease and minimizing toxic effects, providing sufficient but less intense therapy for low-risk disease. This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial.
